347 related articles for article (PubMed ID: 10026993)
21. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer.
Firozi PF; Bondy ML; Sahin AA; Chang P; Lukmanji F; Singletary ES; Hassan MM; Li D
Carcinogenesis; 2002 Feb; 23(2):301-6. PubMed ID: 11872636
[TBL] [Abstract][Full Text] [Related]
22. Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1.
To-Figueras J; Gené M; Gómez-Catalán J; Piqué E; Borrego N; Corbella J
Cancer Lett; 2001 Nov; 173(2):155-62. PubMed ID: 11597790
[TBL] [Abstract][Full Text] [Related]
23. Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma.
Casson AG; Zheng Z; Chiasson D; MacDonald K; Riddell DC; Guernsey JR; Guernsey DL; McLaughlin J
Cancer Detect Prev; 2003; 27(2):139-46. PubMed ID: 12670526
[TBL] [Abstract][Full Text] [Related]
24. N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer.
Lee KM; Park SK; Kim SU; Doll MA; Yoo KY; Ahn SH; Noh DY; Hirvonen A; Hein DW; Kang D
Cancer Lett; 2003 Jul; 196(2):179-86. PubMed ID: 12860276
[TBL] [Abstract][Full Text] [Related]
25. Genetic polymorphisms of phase II metabolic enzymes and lung cancer susceptibility in a population of Central South China.
Chen HC; Cao YF; Hu WX; Liu XF; Liu QX; Zhang J; Liu J
Dis Markers; 2006; 22(3):141-52. PubMed ID: 16788248
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.
Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E
Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921
[TBL] [Abstract][Full Text] [Related]
27. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma.
Casson AG; Zheng Z; Porter GA; Guernsey DL
Cancer Detect Prev; 2006; 30(5):423-31. PubMed ID: 17064856
[TBL] [Abstract][Full Text] [Related]
29. A systematic approach to analysing gene-gene interactions: polymorphisms at the microsomal epoxide hydrolase EPHX and glutathione S-transferase GSTM1, GSTT1, and GSTP1 loci and breast cancer risk.
Spurdle AB; Chang JH; Byrnes GB; Chen X; Dite GS; McCredie MR; Giles GG; Southey MC; Chenevix-Trench G; Hopper JL
Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):769-74. PubMed ID: 17416769
[TBL] [Abstract][Full Text] [Related]
30. CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a Turkish population.
Berber U; Yilmaz I; Yilmaz O; Haholu A; Kucukodaci Z; Ates F; Demirel D
Asian Pac J Cancer Prev; 2013; 14(6):3925-9. PubMed ID: 23886208
[TBL] [Abstract][Full Text] [Related]
31. [Role of gene polymorphisms of phase II of xenobiotic biotransformation from glutathione-S-transferase and N-acetyltransferase families in susceptibility to lung cancer among Mayak workers].
Rusinova GG; Azizova TV; Viazovskaia NS; Glazkova IV; Gur'ianov MIu; Osovets SV
Radiats Biol Radioecol; 2014; 54(4):350-9. PubMed ID: 25775823
[TBL] [Abstract][Full Text] [Related]
32. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer.
Olshan AF; Weissler MC; Watson MA; Bell DA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):185-91. PubMed ID: 10698480
[TBL] [Abstract][Full Text] [Related]
33. CYP1A1, GSTM1 and GSTT1 genetic polymorphisms and gastric cancer risk among Japanese: A nested case-control study within a large-scale population-based prospective study.
Hidaka A; Sasazuki S; Matsuo K; Ito H; Charvat H; Sawada N; Shimazu T; Yamaji T; Iwasaki M; Inoue M; Tsugane S;
Int J Cancer; 2016 Aug; 139(4):759-68. PubMed ID: 27062139
[TBL] [Abstract][Full Text] [Related]
34. Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer.
Brockmöller J; Kaiser R; Kerb R; Cascorbi I; Jaeger V; Roots I
Pharmacogenetics; 1996 Dec; 6(6):535-45. PubMed ID: 9014203
[TBL] [Abstract][Full Text] [Related]
35. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls.
Nyberg F; Hou SM; Hemminki K; Lambert B; Pershagen G
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):875-83. PubMed ID: 9796632
[TBL] [Abstract][Full Text] [Related]
36. Effect of SULT1A1 and NAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenomas.
Tiemersma EW; Bunschoten A; Kok FJ; Glatt H; de Boer SY; Kampman E
Int J Cancer; 2004 Jan; 108(1):97-103. PubMed ID: 14618622
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer.
Zhou W; Liu G; Thurston SW; Xu LL; Miller DP; Wain JC; Lynch TJ; Su L; Christiani DC
Cancer Epidemiol Biomarkers Prev; 2002 Jan; 11(1):15-21. PubMed ID: 11815396
[TBL] [Abstract][Full Text] [Related]
38. Influence of GSTM1, GSTT1, GSTP1, and EPHX gene polymorphisms on DNA adduct level and HPRT mutant frequency in coke-oven workers.
Viezzer C; Norppa H; Clonfero E; Gabbani G; Mastrangelo G; Hirvonen A; Celotti L
Mutat Res; 1999 Dec; 431(2):259-69. PubMed ID: 10635992
[TBL] [Abstract][Full Text] [Related]
39. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
[TBL] [Abstract][Full Text] [Related]
40. GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
Moore LE; Baris DR; Figueroa JD; Garcia-Closas M; Karagas MR; Schwenn MR; Johnson AT; Lubin JH; Hein DW; Dagnall CL; Colt JS; Kida M; Jones MA; Schned AR; Cherala SS; Chanock SJ; Cantor KP; Silverman DT; Rothman N
Carcinogenesis; 2011 Feb; 32(2):182-9. PubMed ID: 21037224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
